Oligo Metastatic renal cell carcinoma: SBRT, if, when and how?

被引：0

作者：

Marvaso, G. ^{[1
]}

Corrao, G. ^{[1
]}

Oneta, O. ^{[1
]}

Gugliandolo, S. G. ^{[1
]}

Pepa, M. ^{[1
]}

Cecconi, A. ^{[1
]}

Gandini, S. ^{[2
]}

Piperno, G. ^{[1
]}

Rocca, M. Cossu ^{[3
]}

Verri, E. ^{[3
]}

Aurilio, G. ^{[3
]}

Corso, F. ^{[2
]}

Cullura, D. ^{[3
]}

Rondi, E. ^{[4
]}

Vigorito, S. ^{[4
]}

Nole, F. ^{[3
]}

Orecchia, R. ^{[5
]}

Jereczek-Fossa, B. A. ^{[1
]}

机构：

[1] IEO European Inst Oncol IRCCS, Div Radiotherapy, Milan, Italy

[2] IEO European Inst Oncol IRCCS, Dept Expt Oncol, Milan, Italy

[3] IEO European Inst Oncol IRCCS, Div Med Oncol, Milan, Italy

[4] IEO European Inst Oncol IRCCS, Unit Med Phys, Milan, Italy

[5] IEO European Inst Oncol IRCCS, Sci Direct, Milan, Italy

来源：

RADIOTHERAPY AND ONCOLOGY | 2020年 / 152卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO-1218

引用

页码：S641 / S642

页数：2

共 50 条

[1] Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso, G.
Corrao, G.
Oneta, O.
Pepa, M.
Zaffaroni, M.
Corso, F.
Gandini, S.
Cecconi, A.
Zerini, D.
Mazzola, G. C.
Augugliaro, M.
Rocca, M. Cossu
Verri, E.
Cattani, F.
La Fauci, F.
Bergamaschi, L.
Luzzago, S.
Mistretta, A. F.
Musi, G.
Nole, F.
De Cobelli, O.
Orecchia, R.
Jereczek-Fossa, B. A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (08): : 1717 - 1726
[2] Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
G. Marvaso
G. Corrao
O. Oneta
M. Pepa
M. Zaffaroni
F. Corso
S. Gandini
A. Cecconi
D. Zerini
G. C. Mazzola
M. Augugliaro
M. Cossu Rocca
E. Verri
F. Cattani
F. La Fauci
L. Bergamaschi
S. Luzzago
A. F. Mistretta
G. Musi
F. Nolè
O. De Cobelli
R. Orecchia
B. A. Jereczek-Fossa
Clinical and Translational Oncology, 2021, 23 : 1717 - 1726
[3] When is metastatic renal cell carcinoma not renal cell carcinoma?
Billings, S.
Henley, J.
JOURNAL OF CUTANEOUS PATHOLOGY, 2007, 34 (01) : 99 - 100
[4] Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma
Cihan, Yasemin Benderli
WORLD JOURNAL OF UROLOGY, 2018, 36 (11) : 1797 - 1798
[5] Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma
Yasemin Benderli Cihan
World Journal of Urology, 2018, 36 : 1797 - 1798
[6] The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).
Barata, Pedro C.
Kotecha, Rupesh
Mendiratta, Prateek
Juloori, Aditya
Angelov, Lilyana
Chao, Samuel T.
Elson, Paul
Koshkin, Vadim S.
Ornstein, Moshe Chaim
Gilligan, Timothy D.
Grivas, Petros
Wood, Laura S.
Rini, Brian I.
Garcia, Jorge A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[7] SBRT FOR OLIGOMETASTATIC RENAL CELL CARCINOMA
Marvaso, Giulia
Corrao, Giulia
Oneta, Olga
Mazzola, Giovanni Carlo
Gugliandolo, Simone Giovanni
Pepa, Matteo
Cecconi, Agnese
Gandini, Sara
Piperno, Gaia
Rocca, Maria Cossu
Verri, Elena
Aurilio, Gaetano
Corso, Federica
Cullura, Daniela
Rondi, Elena
Vigorito, Sabrina
Nole, Franco
Orecchia, Roberto
Jereczek-Fossa, Barbara Alicja
ANTICANCER RESEARCH, 2020, 40 (08) : 4617 - 4618
[8] Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors in metastatic renal cell carcinoma
Peng, Jonathan
Lalani, Aly-Khan
Swaminath, Anand
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021, 15 (08): : 281 - 286
[9] Metastasectomy in patients with renal cell carcinoma: when and how?
Omid, Sara
Abufaraj, Mohammad
Remzi, Mesut
CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 602 - 609
[10] Surgery in renal cell carcinoma—when, whom and how?
Sebastian Lenart
Ingrid Berger
Nikolaus Hartig
Stephan Madersbacher
Anton Ponholzer
memo - Magazine of European Medical Oncology, 2019, 12 : 347 - 351

← 1 2 3 4 5 →